News Troubled 23andMe is exploring a sale of the business Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company.
News 23andMe stock sell-off adds to its woes Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes
News 23andMe ends drug development and slashes staff 23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
News 23andMe board rebuffs CEO plan to take the firm private A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.
Patients Genetic testing update with 23andMe’s Noura Abul-Husn In the latest instalment of the pharmaphorum podcast, editor-in-chief Jonah Comstock is joined by Dr Noura Abul-Husn, VP of genomic health at 23andMe.
News 23andMe, Novartis team up to put Lp(a) on patients’ radar Lipoprotein(a) is well established as a risk factor for cardiovascular disease, but patients rarely get tested for it.
